专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5250665A Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation 失效
标题翻译：具体的β-β交联血红蛋白及其制备方法
公开(公告)号：US5250665A
公开(公告)日：1993-10-05
申请号：US746372
申请日：1991-08-16
申请人： Ronald Kluger , Jolanta Wodzinska
发明人： Ronald Kluger , Jolanta Wodzinska
IPC分类号： A61K38/16 , A61P7/08 , C07K1/00 , C07K1/107 , C07K1/113 , C07K14/00 , C07K14/805 , C07C103/52 , A61K35/14 , C07K13/00
CPC分类号： C07K14/805
摘要： A modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent. The cross-linking reagent is selected such that the .beta.-chains are cross-linked within the 2,3-diphosphoglycerate binding site and the linkage distance between the .beta.-chains is between about 5 to 9 angstroms. A method of preparing the modified hemoglobin and its use as a blood substitute or a plasma expander are also described.
摘要翻译：包含与交联剂交联的血红蛋白的改性血红蛋白。选择交联试剂使得β-链在2,3-二磷酸甘油酸结合位点内交联并且β链之间的连接距离在约5至9埃之间。还描述了制备改性血红蛋白的方法及其作为血液替代物或等离子体扩张剂的用途。

2. 发明授权

US4745210A Preparation process of N-formyl-.alpha.-aspartyl phenylalanine 失效
标题翻译： N-甲酰基-α-天冬氨酰苯丙氨酸的制备方法
公开(公告)号：US4745210A
公开(公告)日：1988-05-17
申请号：US804479
申请日：1985-12-04
申请人： Ryuichi Mita , Toshio Katoh , Chojiro Higuchi , Takeshi Oura , Akihiro Yamaguchi
发明人： Ryuichi Mita , Toshio Katoh , Chojiro Higuchi , Takeshi Oura , Akihiro Yamaguchi
IPC分类号： C07K1/02 , C07K5/06 , C07K5/075 , C07C103/52 , C07C102/00
CPC分类号： C07K5/0613
摘要： This invention relates to an improved process for preparing N-formyl-.alpha.- aspartyl phenylalanine. More specifically, it relates to a process for preparing N-formyl-.alpha.-aspartyl phenylalanine by condensating N-formyl aspartic acid anhydride and phenylalanine which comprises effecting the condensation reaction in a water medium while maintaining the pH during the reaction in the range of 7-12 and at a reaction temperature of 50.degree. C. or below.
摘要翻译：本发明涉及一种制备N-甲酰基-α-天冬氨酰苯丙氨酸的改进方法。更具体地，本发明涉及通过冷凝N-甲酰天冬氨酸酐和苯丙氨酸制备N-甲酰基-α-天冬氨酰苯基丙氨酸的方法，其包括在水介质中进行缩合反应，同时将反应期间的pH保持在7 -12，反应温度为50℃以下。

3. 发明授权

US4725669A Assay for detecting infection by human T-cell lymphotropic virus-III 失效
标题翻译：用于检测人T细胞淋巴细胞病毒III感染的测定
公开(公告)号：US4725669A
公开(公告)日：1988-02-16
申请号：US670361
申请日：1984-11-09
申请人： Myron E. Essex , Tun-Hou Lee
发明人： Myron E. Essex , Tun-Hou Lee
IPC分类号： C07K14/16 , G01N33/569 , C07C103/52 , C07G7/00
CPC分类号： C07K14/005 , G01N33/56988 , C12N2740/16122 , Y10S435/81 , Y10S435/974 , Y10S530/826 , Y10S530/829
摘要： A first glycoprotein having a molecular weight of approximately 120,000 daltons in the H9/HTLV-III cell line, of which approximately 90,000 daltons is the unglycosylated moiety, is obtained from cells infected with human T-cell leukemia virus, type III. A second glycoprotein having a molecular weight of aproximately 160,000 daltons is also obtained from such cells, of which approximately 90,000 daltons is the unglycosylated moiety and is substantially identical to the unglycosylated moiety of the first glycoprotein.The presence, in a biological specimen, of either of these glycoproteins or of the unglycosylated moiety is indicative of the presence of cells infected by human T-cell leukemia virus. An assay for the glycoprotein or its unglycosylated moiety is a useful diagnostic procedure for determining such infection in biological specimens.
摘要翻译：在H9 / HTLV-III细胞系中分子量约为120,000道尔顿的第一糖蛋白，其中约90,000道尔顿是未糖基化的部分，是从感染了人T细胞白血病病毒III型的细胞获得的。还从这样的细胞获得分子量约为160,000道尔顿的第二糖蛋白，其中约90,000道尔顿是未糖基化的部分，并且基本上与第一糖蛋白的未糖基化部分相同。在生物标本中存在这些糖蛋白或未糖基化部分的任何一个表明存在被人T细胞白血病病毒感染的细胞。糖蛋白或其未糖基化部分的测定是用于在生物样品中测定这种感染的有用的诊断程序。

4. 发明授权

US4703038A Combination of dihydropyridines with angiotensin converting enzymes-inhibitors 失效
标题翻译：二氢吡啶与血管紧张素转换酶抑制剂的组合
公开(公告)号：US4703038A
公开(公告)日：1987-10-27
申请号：US785182
申请日：1985-10-07
申请人： Bernward Garthoff , Stanislav Kazda , Andreas Knorr
发明人： Bernward Garthoff , Stanislav Kazda , Andreas Knorr
IPC分类号： C07D211/90 , A61K31/455 , A61K38/00 , A61K38/55 , A61P9/12 , A61K31/44 , A61K37/02 , C07C103/52
CPC分类号： A61K38/556
摘要： The invention concerns a combination of dihydropyridine derivatives with compounds which inhibit the formation of enzymes which control the conversion of angiotensin I into angiotensin II and their use as antihypertensive agents.
摘要翻译：本发明涉及二氢吡啶衍生物与抑制血管紧张素I转化为血管紧张素II的酶的形成的化合物的组合以及它们作为抗高血压药物的用途。

5. 发明授权

US4621135A Novel THF compositions 失效
标题翻译：新型THF组合物
公开(公告)号：US4621135A
公开(公告)日：1986-11-04
申请号：US741753
申请日：1985-06-06
申请人： Nathan Trainin , Yigal Burstein
发明人： Nathan Trainin , Yigal Burstein
IPC分类号： A61K35/24 , A61K38/00 , A61K38/22 , A61P37/00 , A61P37/04 , C07K1/14 , C07K1/20 , C07K5/08 , C07K7/06 , C07K14/435 , A61K37/00 , C07C103/52
CPC分类号： C07K7/065 , A61K38/00 , Y10S514/885 , Y10S930/18
摘要： Novel peptide materials having thymic humoral activity are disclosed having the respective amino acid sequences of:Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu;His-Pro-Leu-Pro-Asp-Leu-Tyr; andPhe-Val-LeuThese novel peptides can be isolated from natural thymus glands or can be prepared synthetically.
摘要翻译：公开了具有胸腺体液活性的新型肽材料，其具有各自的氨基酸序列：Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu; His-Pro-Leu-Pro-Asp-Leu-Tyr; 和Phe-Val-Leu这些新型肽可以从天然胸腺中分离，也可以合成制备。

6. 发明授权

US4618708A Amino acid derivative 失效
标题翻译：氨基酸衍生物
公开(公告)号：US4618708A
公开(公告)日：1986-10-21
申请号：US715764
申请日：1985-03-25
申请人： Bernard Roques , Jean-Charles Schwartz , Jeanne-Marie Lecomte
发明人： Bernard Roques , Jean-Charles Schwartz , Jeanne-Marie Lecomte
IPC分类号： A61K31/195 , A61K31/16 , A61K31/165 , A61K31/215 , A61K31/22 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/445 , A61K31/66 , A61K38/00 , A61P1/12 , A61P25/04 , A61P25/24 , A61P25/26 , C07C67/00 , C07C231/00 , C07C233/51 , C07C237/12 , C07C237/20 , C07C239/20 , C07C239/22 , C07C259/06 , C07C291/04 , C07C301/00 , C07C309/53 , C07C313/00 , C07C317/28 , C07C323/25 , C07C323/59 , C07C323/60 , C07D207/16 , C07D209/20 , C07D295/08 , C07D295/088 , C07F9/22 , C07F9/24 , C07F9/38 , C07F9/40 , C07F9/547 , C07F9/572 , C07F9/59 , C07K5/02 , C07K5/06 , C07K14/575 , C07K14/655 , C07K14/81 , C07C101/24 , C07C103/52
CPC分类号： C07D295/088 , C07D207/16 , C07D209/20 , C07F9/222 , C07F9/2458 , C07F9/2475 , C07F9/3808 , C07F9/3882 , C07K5/06191 , A61K38/00
摘要： Derivatives having the general formula: ##STR1## in which the various radicals A,B,X,R.sub.1, R.sub.2, R.sub.3 and n have indicated definitions. These compounds have in particular enkephalinase-inhibiting, antalgic, antidepressive, antidiarrhea and hypotensive activities.
摘要翻译：具有以下通式的衍生物：其中各种基团A，B，X，R 1，R 2，R 3和n已经表示定义。这些化合物特别是脑啡肽酶抑制，止痛药，抗抑郁药，止泻药和降血压活性。

7. 发明授权

US4551273A Analgesic peptide and process for the preparation thereof 失效
标题翻译：止痛肽及其制备方法
公开(公告)号：US4551273A
公开(公告)日：1985-11-05
申请号：US575804
申请日：1984-01-31
申请人： Shinro Tachibana , Shizuko Ohya , Yoshihiro Arakawa , Takahiro Nakazawa , Takeru Kaneko , Masuhiro Ikeda , Kiyomi Yamatsu
发明人： Shinro Tachibana , Shizuko Ohya , Yoshihiro Arakawa , Takahiro Nakazawa , Takeru Kaneko , Masuhiro Ikeda , Kiyomi Yamatsu
IPC分类号： C07K14/655 , A61K38/00 , A61P25/04 , C07C231/02 , C07K7/08 , C07K14/575 , C07K14/665 , C07C103/52
CPC分类号： C07K14/665 , A61K38/00 , Y02P20/55
摘要： A novel peptide having the primary structure: N-Me-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-D.Ile-Arg-Pro-Lys-D.Leu-Lys-Trp-NH.sub.2 (in which D.Ile and D.Leu represent a D-Ile and a D-Leu residue respectively, other abbreviations of amino acids represent each an L-amino acid residue and Me represents a methyl group), which exhibits a remarkable analgesic effect when administered peripherally. A process for the preparation thereof by a solid phase method is also disclosed.
摘要翻译：具有一级结构的新型肽：N-Me-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-D.Ile-Arg-Pro-Lys-D.Leu-Lys-Trp-NH2（其中D. Ile和D.Leu分别表示D-Ile和D-Leu残基，氨基酸的其它缩写代表每个L-氨基酸残基，Me表示甲基），其在外周施用时显示出显着的镇痛作用。还公开了通过固相法制备其方法。

8. 发明授权

US4544500A Synthetic foot and mouth disease antigen 失效
标题翻译：合成口蹄疫抗原
公开(公告)号：US4544500A
公开(公告)日：1985-10-01
申请号：US682819
申请日：1984-12-18
申请人： James L. Bittle , Richard A. Lerner
发明人： James L. Bittle , Richard A. Lerner
IPC分类号： A61K39/00 , G01N33/569 , C07C103/52
CPC分类号： G01N33/56983 , A61K39/00 , Y10S530/806 , Y10S930/222
摘要： Synthetic antigens in which the principal antigenicity derives from synthetic peptide corresponding to the 130-160 region of the foot-and-mouth disease virus are described.
摘要翻译：描述了其主要抗原性来源于对应于口蹄疫病毒的130-160区域的合成肽的合成抗原。

9. 发明授权

US4540682A Pharmaceutical peptides, preparation, use and intermediates 失效
标题翻译：药物肽，制剂，用途和中间体
公开(公告)号：US4540682A
公开(公告)日：1985-09-10
申请号：US613868
申请日：1984-05-23
申请人： George W. Hardy , Lawrence A. Lowe , Terence W. Smith
发明人： George W. Hardy , Lawrence A. Lowe , Terence W. Smith
IPC分类号： C07K5/08 , A61K38/00 , A61P1/12 , A61P9/06 , A61P9/12 , A61P11/14 , A61P25/04 , A61P25/30 , C07K1/113 , C07K5/065 , C07K5/087 , C07K5/10 , A61K37/00 , C07C103/52
CPC分类号： C07K5/0812 , C07K5/06078 , Y10S514/809
摘要： Novel peptides of formula (I) ##STR1## wherein R.sup.1 is hydrogen, alkyl of 1 or 2 carbon atoms or an amidino group,R.sup.2 is alkyl of 1 or 2 carbon atoms,R.sup.3 is hydrogen or carbamyl,X.sup.2 is a D-radical having the structure: ##STR2## Z.sup.1 and Z.sup.2 are the same or different and each is hydrogen, halo, nitro or trifluoromethyl and at least one is other than hydrogen,m is 2, 3 or 4 andn is 0, 1 or 2,provided that when R.sup.3 is carbamyl then n is always 1;and salts thereof.The compounds have a selectively peripheral analgesic effect when administered to mammals and also exhibit antidiarrhoeal and antitussive activity and may thus be used in human or veterinary medicine for the relief or prevention of pain, for the treatment of diarrhoea or dysentery and for the suppression of cough.
摘要翻译：式（I）的新肽其中R1是氢，1或2个碳原子的烷基或脒基，R2是1或2个碳原子的烷基，R3是氢或氨基甲酰基，X2是D 具有以下结构的化合物：＆lt; IMAGE＆gt; Z1和Z2相同或不同，各自为氢，卤素，硝基或三氟甲基，至少一个不是氢，m为2,3或4，n为0,1或 2，条件是当R 3为氨甲酰基时，则n总是为1; 及其盐。当给予哺乳动物时，这些化合物具有选择性的外周止痛作用，并且还具有抗腹泻和镇咳作用，因此可用于人或兽医学用于缓解或预防疼痛，用于治疗腹泻或痢疾以及抑制咳嗽。

10. 发明授权

US4537770A A41030 antibiotics 失效
标题翻译： A41030抗生素
公开(公告)号：US4537770A
公开(公告)日：1985-08-27
申请号：US662464
申请日：1984-10-18
申请人： Karl H. Michel , Ralph E. Kastner
发明人： Karl H. Michel , Ralph E. Kastner
IPC分类号： A23K1/17 , A23K1/18 , C07K7/06 , C07K9/00 , A61K35/00 , C07C103/52 , C07G7/00
CPC分类号： C12R1/465 , A23K20/195 , A23K50/30 , C07K7/06 , C07K9/008 , Y10S930/19 , Y10S930/27
摘要： Antibiotic A41030, a complex of 7 individual factors, is produced by submerged, aerobic fermentation of new Streptomyces virginiae NRRL 12525, and Streptomyces virginiae NRRL 15156. The antiobiotic factors are separated and possess antibacterial activity against Staphylococcus and Streptococcus species which are penicillin resistant. In addition, the antibiotic factors have shown inhibition of Streptococcus pneumonia Park I. The complex and the individual factors enhance feed efficiency in ruminant animals, and are growth promoters in chickens and swine, and are especially valuable in milk production in dairy cattle.
摘要翻译：抗生素A41030是7种独立因子的复合物，通过新的链霉菌NRRL 12525和牛链霉菌NRRL 15156的浸没，好氧发酵产生。抗生素因子被分离并且具有抗青霉素抗性的葡萄球菌和链球菌属的抗菌活性。此外，抗生素因子已经显示出对肺炎链球菌Park I的抑制作用。复合物和个体因素提高了反刍动物的饲料效率，是鸡和猪的生长促进剂，在奶牛生产中特别有价值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式